Respiratory syncytial virus vaccine

A respiratory syncytial virus vaccine, or RSV vaccine, is a vaccine that protects against respiratory syncytial virus.[1] RSV affects an estimated 64 million people and causes 160,000 deaths worldwide each year.[2]

The RSV vaccines Arexvy (GSK),[3] Abrysvo (Pfizer),[4] and Mresvia (Moderna)[5] are approved for medical use in the United States.[6][7][8] Arexvy is approved for medical use in the United States,[3] in the European Union,[1][9] and in Canada for adults aged 60 years of age and older.[10] Arexvy is approved in the US for adults aged 50–59 years of age who are at increased risk.[6][11][12] In June 2024, the US Centers for Disease Control and Prevention (CDC) updated its recommendation for the use of respiratory syncytial virus vaccine in people aged 60 years of age and older.[13] The CDC recommends that people who have not received the respiratory syncytial virus vaccine and are aged 75 years of age and older receive the respiratory syncytial virus vaccine; and that people who have not received the respiratory syncytial virus vaccine and are aged 60–74 years of age who are at increased risk of severe respiratory syncytial virus, meaning they have certain chronic medical conditions, such as lung or heart disease, or they live in nursing homes, receive the respiratory syncytial virus vaccine.[13][14]

A 2013 study led to the approval of RSV vaccines.[15][16] Work on RSV vaccines also supported the rapid development of COVID-19 vaccines.[16][17]

  1. ^ a b Cite error: The named reference Arexvy EPAR was invoked but never defined (see the help page).
  2. ^ "Respiratory Syncytial Virus (RSV) – NIH: National Institute of Allergy and Infectious Diseases". National Institute of Allergy and Infectious Diseases. 22 July 2022. Archived from the original on 24 April 2023. Retrieved 24 April 2023.
  3. ^ a b Cite error: The named reference Arexvy FDA label was invoked but never defined (see the help page).
  4. ^ Cite error: The named reference Abrysvo FDA label was invoked but never defined (see the help page).
  5. ^ Cite error: The named reference Mresvia FDA label was invoked but never defined (see the help page).
  6. ^ a b Cite error: The named reference FDA Arexvy was invoked but never defined (see the help page).
  7. ^ "Abrysvo". U.S. Food and Drug Administration (FDA). 1 June 2023. Retrieved 2 June 2023.
  8. ^ "US FDA approves Pfizer's RSV vaccine". Reuters. 31 May 2023. Archived from the original on 22 August 2023. Retrieved 1 June 2023.
  9. ^ Cite error: The named reference EU Arexvy Product Information was invoked but never defined (see the help page).
  10. ^ La Grassa J (4 August 2023). "Health Canada approves 1st RSV vaccine for people 60 and older". CBC News. Canadian Broadcasting Corporation. Archived from the original on 13 September 2023. Retrieved 9 September 2023.
  11. ^ "US FDA approves expanded age indication for GSK's Arexvy, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk". GSK (Press release). 7 June 2024. Archived from the original on 10 June 2024. Retrieved 11 June 2024.
  12. ^ "FDA approval letter". Food and Drug Administration. Archived from the original on 11 June 2024. Retrieved 11 June 2024.
  13. ^ a b "CDC Updates RSV Vaccination Recommendation for Adults". U.S. Centers for Disease Control and Prevention (CDC). 26 June 2024. Archived from the original on 7 July 2024. Retrieved 27 June 2024. Public Domain This article incorporates text from this source, which is in the public domain.
  14. ^ Mandavilli A (26 June 2024). "Federal Officials Revise Recommendations for R.S.V. Vaccine". The New York Times. Archived from the original on 27 June 2024. Retrieved 27 June 2024.
  15. ^ Cite error: The named reference science2013 was invoked but never defined (see the help page).
  16. ^ a b Cite error: The named reference sa-202303 was invoked but never defined (see the help page).
  17. ^ Graham BS (February 2023). "The Journey to RSV Vaccines — Heralding an Era of Structure-Based Design". The New England Journal of Medicine. 388 (7): 579–581. doi:10.1056/NEJMp2216358. PMID 36791157. S2CID 256900516.